Developer docs
API playgroundTry for free, no card

Search company profiles

Altacor

Full company profile

uuid000691q

Namestring
Altacor
Legal namestring
Altacor
Company typeenum
Private
Founded yearint
2007
Short descriptiontext

Altacor is a UK-based specialist ophthalmology company that develops and sells the Clinitas brand of sodium hyaluronate dry eye treatments and carbomer lubricating gel to individual consumers and eye care professionals, primarily through UK direct-to-consumer e-commerce.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersReading, United Kingdom
HQ citystring
Reading
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, dry eye treatment, sodium hyaluronate drops, ocular lubrication products, lubricating eye gel
Industry1 code
PRIMARYHLAHAJAF
Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code3 codes
  • Ophthalmic Goods Manufacturing339115
  • Optical Goods Retailers45613
  • Ophthalmic Goods Merchant Wholesalers423460
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmic Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Consumer Product Sales
TypeOne Time License
Description

Altacor generates revenue through direct-to-consumer sales of its Clinitas branded ophthalmic products (eye drops and gel) via e-commerce. Products are sold as one-time purchases with volume discounts available for multi-pack orders.

clinitas.co.uk
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Pricing details3 tiers
1Clinitas 0.2% Ease eye drops - From £8.99
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Single multi-dose bottle at £11.99; Daily-dose vials also available. Multi-pack discounts available (3-pack saves £7.98, 6-pack saves £28.95).

clinitas.co.uk
2Clinitas 0.4% Soothe eye drops - From £9.99
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Single pack at £11.99; Multi-pack discounts available (3-pack saves £5.98, 6-pack saves £26.95).

clinitas.co.uk
3Clinitas Gel Hydrate - From £5.99
ModelUnit PricingBilling cadencePay-as-you-go
Notes

1 Pack at £5.99; Multi-pack discounts available (3-pack saves £1.98, 6-pack saves £8.95).

clinitas.co.uk
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Clinitas
Description

Dry eye treatment product line including Clinitas 0.2% Ease, Clinitas 0.4% Soothe, and Clinitas Gel Hydrate, formulated with sodium hyaluronate for ocular surface relief.

clinitas.co.uk
Core offering1 text field

Altacor develops, manufactures, and sells the Clinitas brand of ophthalmic products for the treatment of dry eye symptoms. The portfolio includes two sodium hyaluronate eye drop concentrations (Clinitas 0.2% Ease and Clinitas 0.4% Soothe) and a carbomer 980-based lubricating gel (Clinitas Gel Hydrate), formulated with high-molecular weight sodium hyaluronate to provide long-lasting ocular surface hydration. Products are sold primarily via the company's UK direct-to-consumer e-commerce store (clinitas.co.uk), with institutional use by the NHS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Trusted by NHS since 2007
+1 more record
Product overview1 text field

Altacor is a UK-based specialist ophthalmology company acquired by Fidia Farmaceutici in April 2026. The company offers the Clinitas brand of dry eye treatment products, which includes sodium hyaluronate-based eye drops in two concentrations (0.2% Ease and 0.4% Soothe) and a carbomer-based lubricating gel (Clinitas Gel Hydrate). These products provide targeted relief for dry eye symptoms through scientifically formulated ophthalmic solutions, with a 15+ year history of NHS trust and endorsement from eyecare professionals.

Product and service3 records
1Clinitas 0.2% Ease
CategoryOphthalmic Eye Drops
Description

Ophthalmic solution of high-molecular weight sodium hyaluronate at 0.2% concentration designed to lubricate, moisturize, and protect the tear film. Provides relief from dry eye symptoms such as irritation, dryness, burning, and foreign body sensation. Available in multi-dose bottles and daily-dose vials, and suitable for use with contact lenses. Targeted at individual consumers experiencing mild dry eye symptoms and at eye care professionals recommending treatment to patients.

2Clinitas 0.4% Soothe
CategoryOphthalmic Eye Drops
Description

Ophthalmic solution of high-molecular weight sodium hyaluronate at 0.4% concentration providing long-lasting, more intensive lubrication and protection for the ocular surface. Targeted at individuals with more severe or persistent dry eye symptoms and used by eye care professionals as a first-choice lubricating drop. Available in multi-dose bottles and daily-dose vials.

3Clinitas Gel Hydrate
CategoryOphthalmic Lubricating Gel
Description

Lubricating carbomer 980 eye gel for relief of dry eye discomfort. Provides cooling and soothing relief for sore, gritty, and itchy eyes, and is used for nighttime relief or when a more viscous solution than drops is required. Targeted at individual consumers with dry eye symptoms and at eye care professionals who recommend it as part of dry eye management.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthersAnnounced on2026-04-21
Description

Fidia Farmaceutici, an Italian pharmaceutical company, acquired UK-based specialist ophthalmology company Altacor. The acquisition brings Altacor's growing portfolio including Clinitas dry eye treatment products into Fidia's ophthalmology portfolio. This represents a significant ownership change, with Altacor becoming a subsidiary of the Italian pharmaceutical group.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Scope Ophthalmics markets the Hycosan range of sodium hyaluronate-based dry eye drops in the UK, directly competing with Clinitas on formulation, channel (NHS + pharmacy), and target prescriber base.

TypeDirect peer
Description

Thea Pharmaceuticals is a European specialty ophthalmology company whose Thealoz Duo combines trehalose and sodium hyaluronate for dry eye, competing head-to-head with Clinitas in UK and European optometry and ophthalmology channels.

TypeBroad incumbent
Description

Alcon's Systane is a global market-leading dry eye lubricant brand available in UK pharmacy and optometry channels, representing the principal mass-market incumbent competing with Clinitas.

TypeBroad incumbent
Description

Bausch + Lomb's Artelac range is a long-established European dry eye lubricant brand distributed through UK pharmacies and optometrists, overlapping with Clinitas on patient base and channel.

TypeBroad incumbent
Description

Reckitt's Optrex is a UK household OTC eye care brand sold in mass-market pharmacy and grocery channels, competing with Clinitas on consumer-facing dry eye shelf space and brand awareness.

6Santen Pharmaceutical
TypeBroad incumbent
Description

Santen is a Japanese specialty ophthalmology company with a broad dry eye portfolio including Hyalein and Cationorm, competing with Clinitas across European prescription and OTC channels.

TypeBroad incumbent
Description

Johnson & Johnson Vision's Blink and Refresh Tears brands are mass-market dry eye lubricants sold globally and in the UK, competing directly with Clinitas on consumer-facing positioning and pharmacy distribution.

TypeBroad incumbent
Description

AbbVie's Allergan Aesthetics division owns the Refresh dry eye brand, a global incumbent in lubricant eye drops that competes with Clinitas on UK pharmacy shelves and optometrist recommendations.

TypeEmerging player
Description

Novaliq is a German specialty ophthalmology company developing water-free and cationic emulsion dry eye therapies (NovaTears, Evotears), offering a more differentiated mechanism of action than traditional HA-based products like Clinitas.

TypeEmerging player
Description

Ocular Therapeutix is a US-based specialty ophthalmology company focused on sustained-release ocular drug delivery and dry eye therapeutics, representing an emerging adjacent competitor in the broader dry eye treatment space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Altacor

Ophthalmic Pharmaceuticalsaltacor-pharma.com

Altacor is a UK-based specialist ophthalmology company that develops and sells the Clinitas brand of sodium hyaluronate dry eye treatments and carbomer lubricating gel to individual consumers and eye care professionals, primarily through UK direct-to-consumer e-commerce.

Altacor firmographics

Firmographics
Name
Altacor
Legal name
Altacor
Website
https://altacor-pharma.com
Company type
Private
Founded year
2007
Operating status
Acquired
Headcount range
11–50 employees
Short description
Altacor is a UK-based specialist ophthalmology company that develops and sells the Clinitas brand of sodium hyaluronate dry eye treatments and carbomer lubricating gel to individual consumers and eye care professionals, primarily through UK direct-to-consumer e-commerce.
Ownership category
akta.pro rank

Altacor industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115), Optical Goods Retailers (45613), Ophthalmic Goods Merchant Wholesalers (423460)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAF
Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ophthalmic pharmaceuticals
  • Dry eye treatment
  • Sodium hyaluronate drops
  • Ocular lubrication products
  • Lubricating eye gel

Where Altacor is headquartered

Location

Headquarters

HQ city
Reading
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Altacor business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Consumer Product Sales: Altacor generates revenue through direct-to-consumer sales of its Clinitas branded ophthalmic products (eye drops and gel) via e-commerce. Products are sold as one-time purchases with volume discounts available for multi-pack orders.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goClinitas 0.2% Ease eye drops - From £8.99
Unit PricingPay-as-you-goClinitas 0.4% Soothe eye drops - From £9.99
Unit PricingPay-as-you-goClinitas Gel Hydrate - From £5.99

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Altacor product offering

Product offering

Core offering

Altacor develops, manufactures, and sells the Clinitas brand of ophthalmic products for the treatment of dry eye symptoms. The portfolio includes two sodium hyaluronate eye drop concentrations (Clinitas 0.2% Ease and Clinitas 0.4% Soothe) and a carbomer 980-based lubricating gel (Clinitas Gel Hydrate), formulated with high-molecular weight sodium hyaluronate to provide long-lasting ocular surface hydration. Products are sold primarily via the company's UK direct-to-consumer e-commerce store (clinitas.co.uk), with institutional use by the NHS.

Product overview

Altacor is a UK-based specialist ophthalmology company acquired by Fidia Farmaceutici in April 2026. The company offers the Clinitas brand of dry eye treatment products, which includes sodium hyaluronate-based eye drops in two concentrations (0.2% Ease and 0.4% Soothe) and a carbomer-based lubricating gel (Clinitas Gel Hydrate). These products provide targeted relief for dry eye symptoms through scientifically formulated ophthalmic solutions, with a 15+ year history of NHS trust and endorsement from eyecare professionals.

Differentiator

Problem solved

Functional benefit

Brands

  • Clinitas: Dry eye treatment product line including Clinitas 0.2% Ease, Clinitas 0.4% Soothe, and Clinitas Gel Hydrate, formulated with sodium hyaluronate for ocular surface relief.

Products and services

  • Clinitas 0.2% Ease Ophthalmic solution of high-molecular weight sodium hyaluronate at 0.2% concentration designed to lubricate, moisturize, and protect the tear film. Provides relief from dry eye symptoms such as irritation, dryness, burning, and foreign body sensation. Available in multi-dose bottles and daily-dose vials, and suitable for use with contact lenses. Targeted at individual consumers experiencing mild dry eye symptoms and at eye care professionals recommending treatment to patients.
  • Clinitas 0.4% Soothe Ophthalmic solution of high-molecular weight sodium hyaluronate at 0.4% concentration providing long-lasting, more intensive lubrication and protection for the ocular surface. Targeted at individuals with more severe or persistent dry eye symptoms and used by eye care professionals as a first-choice lubricating drop. Available in multi-dose bottles and daily-dose vials.
  • Clinitas Gel Hydrate Lubricating carbomer 980 eye gel for relief of dry eye discomfort. Provides cooling and soothing relief for sore, gritty, and itchy eyes, and is used for nighttime relief or when a more viscous solution than drops is required. Targeted at individual consumers with dry eye symptoms and at eye care professionals who recommend it as part of dry eye management.

Quantifiable outcome

  • Trusted by NHS since 2007
  • +1 more outcomes

Companies that use Altacor

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Altacor technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Altacor partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Fidia FarmaceuticicoreOthers · 21 April 2026Fidia Farmaceutici, an Italian pharmaceutical company, acquired UK-based specialist ophthalmology company Altacor. The acquisition brings Altacor's growing portfolio including Clinitas dry eye treatment products into Fidia's ophthalmology portfolio. This represents a significant ownership change, with Altacor becoming a subsidiary of the Italian pharmaceutical group.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Altacor competitors and assessment

Company assessment

Direct peers

  • Scope Ophthalmics (Hycosan): Scope Ophthalmics markets the Hycosan range of sodium hyaluronate-based dry eye drops in the UK, directly competing with Clinitas on formulation, channel (NHS + pharmacy), and target prescriber base.
  • Thea Pharmaceuticals (Thealoz Duo): Thea Pharmaceuticals is a European specialty ophthalmology company whose Thealoz Duo combines trehalose and sodium hyaluronate for dry eye, competing head-to-head with Clinitas in UK and European optometry and ophthalmology channels.

Broad incumbents

  • Alcon (Systane): Alcon's Systane is a global market-leading dry eye lubricant brand available in UK pharmacy and optometry channels, representing the principal mass-market incumbent competing with Clinitas.
  • Bausch + Lomb (Artelac): Bausch + Lomb's Artelac range is a long-established European dry eye lubricant brand distributed through UK pharmacies and optometrists, overlapping with Clinitas on patient base and channel.
  • Reckitt Benckiser (Optrex): Reckitt's Optrex is a UK household OTC eye care brand sold in mass-market pharmacy and grocery channels, competing with Clinitas on consumer-facing dry eye shelf space and brand awareness.
  • Santen Pharmaceutical: Santen is a Japanese specialty ophthalmology company with a broad dry eye portfolio including Hyalein and Cationorm, competing with Clinitas across European prescription and OTC channels.
  • Johnson & Johnson Vision (Blink / Refresh): Johnson & Johnson Vision's Blink and Refresh Tears brands are mass-market dry eye lubricants sold globally and in the UK, competing directly with Clinitas on consumer-facing positioning and pharmacy distribution.
  • AbbVie / Allergan (Refresh): AbbVie's Allergan Aesthetics division owns the Refresh dry eye brand, a global incumbent in lubricant eye drops that competes with Clinitas on UK pharmacy shelves and optometrist recommendations.

Emerging players

  • Novaliq (NovaTears / Evotears): Novaliq is a German specialty ophthalmology company developing water-free and cationic emulsion dry eye therapies (NovaTears, Evotears), offering a more differentiated mechanism of action than traditional HA-based products like Clinitas.
  • Ocular Therapeutix: Ocular Therapeutix is a US-based specialty ophthalmology company focused on sustained-release ocular drug delivery and dry eye therapeutics, representing an emerging adjacent competitor in the broader dry eye treatment space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Altacor social profiles

Digital presence

Altacor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Altacor leadership team

Management profile

Number of profiles

Profiles1 record

Altacor funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Altacor M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altacor

What does Altacor do?

Altacor develops, manufactures, and sells the Clinitas brand of ophthalmic products for the treatment of dry eye symptoms. The portfolio includes two sodium hyaluronate eye drop concentrations (Clinitas 0.2% Ease and Clinitas 0.4% Soothe) and a carbomer 980-based lubricating gel (Clinitas Gel Hydrate), formulated with high-molecular weight sodium hyaluronate to provide long-lasting ocular surface hydration. Products are sold primarily via the company's UK direct-to-consumer e-commerce store (clinitas.co.uk), with institutional use by the NHS.

Is Altacor a public or private company?

Altacor is a private company. It is classified as corporate owned and is currently acquired.

When was Altacor founded?

Altacor was founded in 2007. It employs 11 to 50 people.

Where is Altacor based?

Altacor is headquartered in Reading, United Kingdom, in the Europe region.

How does Altacor make money?

One revenue line is on record: consumer Product Sales.

Who are Altacor's main competitors?

Direct peers on record are Scope Ophthalmics (Hycosan) and Thea Pharmaceuticals (Thealoz Duo). Broad incumbents are Alcon (Systane), Bausch + Lomb (Artelac), Reckitt Benckiser (Optrex), Santen Pharmaceutical, Johnson & Johnson Vision (Blink / Refresh) and AbbVie / Allergan (Refresh). Emerging players are Novaliq (NovaTears / Evotears) and Ocular Therapeutix.

Does Altacor have an API?

No public API is recorded for Altacor.

What industry is Altacor in?

Altacor's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAJAF, Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Fidia FarmaceuticiTwo new acquisitions in Europe, in the UK and RomaniaFidia Farmaceutici acquired Altacor Ltd in the UK and Meditrina Romania S.r.l in Romania, using internal funds. The moves are part of a 2025-2026 investment plan of about 150 million euros to strengthen its global presence. The acquisitions aim to create synergies in ophthalmology and medical devices.AbdoFidia Farma acquires UK’s AltacorFidia Farmaceutici acquired 100% of UK ophthalmology firm Altacor, expanding its UK presence and adding products like artificial tears and diagnostic stains. The deal is part of a €150m investment plan for 2025-26, alongside the acquisition of Romanian firm Meditrina. Fidia reported 2024 revenues exceeding €500m, up 10.1% year-on-year.PharmiWeb.comFidia Farmaceutici enters the UK market with the acquisition of Altacor LtdFidia Farmaceutici has acquired 100% of Altacor Ltd, a UK-based specialist ophthalmology company, marking its direct entry into the rapidly-growing UK ophthalmology market. The company also announced the acquisition of Meditrina Pharmaceuticals S.r.l., a Romanian distribution company, both forming part of a broader €150 million investment plan for the 2025-26 period. Fidia plans to leverage Altacor's existing portfolio and distribution channels to introduce its hyaluronic acid-based eye care products, including artificial tears and surgical platforms, to the UK market.The Pharma LetterFidia Farmaceutici enters UK market with acquisition of AltacorItalian pharma company Fidia Farmaceutici announced the acquisition of 100% of the share capital of Altacor, a UK-based specialist ophthalmology company. Altacor owns a growing portfolio including Clinitas, a dedicated product line for dry eye treatment. The acquisition marks Fidia Farmaceutici's entry into the UK market.pageOT focuses on…dry eyeGrafton Optical launched AB Max, a five-to-seven-minute eyelid margin cleansing treatment for blepharitis. Positive Impact introduced hot compresses for dry eye, and Scope added tea tree oil cleansing gel. Altacor, Visufarma, and others also released new dry eye products.GlobeNewswireNicOx Board decides not to exercise its option to acquire the remaining shares of AltacorNicOx's board decided not to exercise its option to acquire the remaining 88.2% of Altacor, leaving NicOx with an 11.8% stake. The option lapsed on May 31, 2012, and NicOx will continue pursuing in-licensing or acquisitions to build its ophthalmology portfolio.GlobeNewswireNicOx appoints Philippe Masquida EVP, Managing Director of European Operations ; Next step in the Company's strategy to create an international ophthalmology companyNicOx appointed Philippe Masquida as Executive Vice President and Managing Director of European Operations, leading European subsidiaries and commercial opportunities. The appointment supports NicOx's strategy to build an international late-stage ophthalmology company, following the acquisition of 11.8% of UK firm Altacor.GlobeNewswireNicOx's web conference on March 21 - NicOx enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology businessNicOx will hold a web conference on March 21, 2012, with its CEO and CFO. The company entered an option agreement to acquire Altacor as a first step toward building an international ophthalmology business. The conference will be available for replay from March 22 to March 28.GlobeNewswireNICOX : Jerry St. Peter appointed Executive Vice President and General Manager of NicOx Inc.NicOx appointed Jerry St. Peter as Executive Vice President and General Manager of its U.S. subsidiary, NicOx Inc. He will lead the U.S. ophthalmology business and identify North American opportunities, reporting to CEO Michele Garufi. The appointment supports NicOx's strategy to build an international ophthalmology company, including an acquisition of 11.8% of Altacor.GlobeNewswireNicOx enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology businessNicOx entered an option agreement to acquire Altacor, investing £2 million for an 11.8% stake and an exclusive option to buy the remaining shares for £9 million. The deal includes potential additional payments up to £8.5 million if milestones are met, with the option exercisable until May 31, 2012.